medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2022, Número 3

<< Anterior Siguiente >>

Arch Neurocien 2022; 27 (3)


Primary CNS lymphoma of diffuse B cells in a patient with neurofibromatosis type 1: A case report

Ramirez-Loera C, Sandoval-López D, Mejía-Pérez S

Idioma: Ingles.
Referencias bibliográficas: 17
Paginas: 64-67
Archivo PDF: 247.67 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Citterio G, Reni M, Gatta G, Ferreri AJM. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017;113:97-110.

  2. Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, et al. [French brain tumor database: general results on40,000 cases, main current applications and future prospects]. Neurochirurgie. 2012;58(1):4-13.

  3. Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, et al. Trends in primary central nervous system lymphoma incidenceand survival in the U.S. Br J Haematol. 2016;174(3):417-24.

  4. Zacharia TT, Law M, Naidich TP, Leeds NE. Central nervous system lymphoma characterization by diffusion-weighted imaging and MRspectroscopy. J Neuroimaging. 2008;18(4):411-7.

  5. Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, et al. Comparison of cancer prevalence in patients with neurofibromatosistype 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open. 2021;4(3):e210945.

  6. Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I, et al. A prospective study of neurofibromatosis type 1 cancer incidencein the UK. Br J Cancer. 2006;95(2):233-8.

  7. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1-11.

  8. Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, et al. Modern concepts in the biology, diagnosis, differential diagnosis andtreatment of primary central nervous system lymphoma. Leukemia. 2011;25(12):1797-807.

  9. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy forprimary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-47.

  10. Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presentingas space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005;31(1):100-5.

  11. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: report of 248 cases.J Neurosurg. 2000;92(2):261-6.

  12. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5(6):477-85.

  13. Ricciardone MD, Ozçelik T, Cevher B, Ozdağ H, Tuncer M, Gürgey A, et al. Human MLH1 deficiency predisposes to hematologicalmalignancy and neurofibromatosis type 1. Cancer Res. 1999;59(2):290-3.

  14. Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, et al. Mutations of CARD11 but not TNFAIP3 may activate theNF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol. 2010;120(4):529-35.

  15. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.

  16. Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br JCancer. 1994;70(5):969-72.

  17. Bühring U, Herrlinger U, Krings T, Thiex R, Weller M, Küker W. MRI features of primary central nervous system lymphomas at presentation.Neurology. 2001;57(3):393-6.




2020     |     www.medigraphic.com